A Phase 3, Randomized, Double-blind, Parallel-group, Vehicle Controlled, Multicenter Study of the Efficacy and Safety of Granexin Gel in the Treatment of Diabetic Foot Ulcer (GAIT 1)
Latest Information Update: 09 Jun 2022
At a glance
- Drugs ACT 1 (Primary)
- Indications Diabetic foot ulcer
- Focus Registrational; Therapeutic Use
- Acronyms GAIT 1
- Sponsors Xequel Bio
- 27 May 2020 Status changed from active, no longer recruiting to discontinued.
- 24 Feb 2020 Status changed from recruiting to active, no longer recruiting.
- 19 Feb 2020 Planned End Date changed from 1 May 2020 to 1 Feb 2021.